Here, we assume that HIF1A is produced by both tumor and non-tumor cells at the microenvironment, contributing to this immune cell recruitment, but it will be important to determine which population is the main contributor to pursue possible therapeutic applications. This evidence concerns the gene HIF1A and neoplasm.